Who owns BRIDGEBIO ONCOLOGY THERAPEUT?
- Ticker: BBOT
- CUSIP Number: 107924102
Tip: Access positions for across all investors
Analyze quarterly positions in Bridgebio Oncology Therapeut with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Bridgebio Oncology Therapeut stock
Who bought or sold BRIDGEBIO ONCOLOGY THERAPEUT this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Cormorant Asset Management | 18M | $224M | 0% | Dec 2025 |
|
| Deerfield Management Company | 4.9M | $61M | 0% | Dec 2025 |
|
| Omega Fund Management | 3.3M | $41M | 0% | Dec 2025 |
|
| Wellington Management Company | 2.9M | $36M | -2% | Dec 2025 |
|
| EcoR1 Capital | 2.8M | $35M | 0% | Dec 2025 |
|
| Alphabet | 2.8M | $25M | 0% | Mar 2026 |
|
| Enavate Sciences GP | 2.6M | $33M | 0% | Dec 2025 |
|
| Citadel Advisors | 2.5M | $32M | 0% | Dec 2025 |
|
| Paradigm Biocapital Advisors | 2.3M | $28M | 21% | Dec 2025 |
|
| BlackRock | 2.1M | $19M | 0% | Mar 2026 |
|
| Novo A/S | 2.0M | $25M | 0% | Dec 2025 |
|
| Laurion Capital Management | 1.5M | $18M | 40% | Dec 2025 |
|
| Adage Capital Partners GP | 1.4M | $18M | -6% | Dec 2025 |
|
| Eventide Asset Management | 1.1M | $13M | 0% | Dec 2025 |
|
| Octagon Capital Advisors | 1.0M | $13M | 0% | Dec 2025 |
|
| Aisling Capital Management | 1.0M | $9.1M | 80% | Mar 2026 |
|
| Vanguard Group | 791k | $9.9M | 22% | Dec 2025 |
|
| Royce & Associates | 637k | $5.7M | 100% | Mar 2026 |
|
| Geode Capital Management | 562k | $7.0M | 4% | Dec 2025 |
|
| Vanguard Capital Management | 538k | $4.8M | 100% | Mar 2026 |
|
| Catalio Capital Management | 411k | $31M | 100% | Dec 2025 |
|
| Ensign Peak Advisors | 321k | $2.9M | 100% | Mar 2026 |
|
| Casdin Capital | 282k | $3.5M | 0% | Dec 2025 |
|
| Charles Schwab Investment Management | 279k | $3.5M | 0% | Dec 2025 |
|
| Vanguard Fiduciary Trust | 254k | $2.3M | 100% | Mar 2026 |
|
| Millennium Management | 241k | $3.0M | -35% | Dec 2025 |
|
| FMR | 240k | $3.0M | 48% | Dec 2025 |
|
| HighVista Strategies | 229k | $2.9M | 100% | Dec 2025 |
|
| ADAR1 Capital Management | 226k | $2.8M | -55% | Dec 2025 |
|
| Ikarian Capital | 220k | $2.8M | -10% | Dec 2025 |
|
| State Street Corporation | 218k | $2.7M | 24% | Dec 2025 |
|
| Sio Capital Management | 131k | $1.6M | 0% | Dec 2025 |
|
| Hudson Bay Capital Management | 110k | $985k | 100% | Mar 2026 |
|
| Woodline Partners | 104k | $1.3M | 0% | Dec 2025 |
|
| Moore Capital Management | 100k | $1.3M | 0% | Dec 2025 |
|
| Goldman Sachs Group | 95k | $1.2M | 100% | Dec 2025 |
|
| Bnp Paribas Arbitrage, Snc | 91k | $813k | 243% | Mar 2026 |
|
| Stempoint Capital | 87k | $1.1M | -54% | Dec 2025 |
|
| Tema Etfs | 82k | $735k | 100% | Mar 2026 |
|
| Renaissance Technologies | 74k | $930k | 100% | Dec 2025 |
|
| Boothbay Fund Management | 67k | $839k | -31% | Dec 2025 |
|
| Northern Trust | 58k | $727k | -40% | Dec 2025 |
|
| TD Asset Management | 58k | $515k | -51% | Mar 2026 |
|
| Manufacturers Life Insurance Company | 54k | $670k | 100% | Dec 2025 |
|
| UBS Group | 51k | $452k | -46% | Mar 2026 |
|
| Avidity Partners Management | 44k | $369k | 100% | Mar 2026 |
|
| Qube Research & Technologies | 36k | $450k | 100% | Dec 2025 |
|
| Acadian Asset Management | 29k | $260k | 100% | Mar 2026 |
|
| XTX Topco | 29k | $359k | 22% | Dec 2025 |
|
| Point72 Asset Management | 24k | $295k | 100% | Dec 2025 |
|
| Vanguard Global Advisers | 18k | $163k | 100% | Mar 2026 |
|
| Axq Capital | 17k | $155k | 100% | Mar 2026 |
|
| Quadrature Capital | 13k | $162k | 100% | Dec 2025 |
|
| Squarepoint Ops | 12k | $144k | 100% | Dec 2025 |
|
| Atlantic Trust | 5.0k | $63k | 100% | Dec 2025 |
|
| Rockefeller Capital Management | 700.00 | $6.3k | 0% | Mar 2026 |
|
| Wells Fargo & Company | 300.00 | $2.7k | 0% | Mar 2026 |
|
| Caitong International Asset Management | 4.00 | $36.000000 | 100% | Mar 2026 |
|
Who sold out of Bridgebio Oncology Therapeut?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Silverarc Capital Management | Sep 2025 | 457k | $5.3M |
| Persistent Asset Partners | Dec 2025 | 8.6k | $108k |